undamentalytics Newsletter
Sign in

Atossa Therapeutics, Inc. (ATOS) stock

Add to watchlist

Add holding +

NASDAQ: ATOS Nasdaq Biotechnology Next results ~November 9, 2026

Atossa Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds13 adding, 14 cuttingOf 2 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 9, 2026 (estimated)

Current signal Revenue growth accelerating: TTM revenue growth rose to -35.2% (+36.2pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 42060.4 points on a year ago.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 35.2% over the last 12 months.
  • Loss-making. Operating margin is -459752.8%: costs exceed revenue.
  • Heavy stock-based pay. Stock pay equals 48701.6% of revenue: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 91% and a beta of 0.7 against the S&P 500.
  • Gross margin slipping. Gross margin is down 93126.9 points on a year ago.

Latest results: FY2016 Q3

Filed November 14, 2016
Earnings per share
-$0.95 against an average estimate of -$1.10: beat by 13.6%
Share reaction
-2.1% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500

Atossa Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+6.0%
  • 1 week-6.1%
  • 1 month-1.7%
  • This year-74.0%
  • 1 year-82.8%
  • 5 years-94.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 7, 2026
Next results (est.)
November 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Agreement
  2. Announcement
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Atossa Therapeutics, Inc. valuation models and calculator

No model value for Atossa Therapeutics, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

12 /100

Weak moat

How hard Atossa Therapeutics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -53.0% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -13706.2%; its worst year was -501813.2%.

  • Discipline 0 / 20

    The diluted share count rose 6502.0% over five years; stock-based pay has been a median 946.6% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$3.56 +12% — 0%
Next −$3.30 +7% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −19.1% on 90 days ago. In the last 30 days, 1 analyst raised Atossa Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Atossa Therapeutics, Inc., last 90 days
−$6.00 −$4.00 −$2.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$4.40 Current fiscal year, 60 days ago: −$4.40 Current fiscal year, 30 days ago: −$4.40 Current fiscal year, 7 days ago: −$4.40 Current fiscal year, Now: −$3.56 −$3.56 Next fiscal year, 90 days ago: −$4.38 Next fiscal year, 60 days ago: −$4.38 Next fiscal year, 30 days ago: −$4.38 Next fiscal year, 7 days ago: −$4.38 Next fiscal year, Now: −$3.30 −$3.30

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$4.40−$4.38
60 days ago −$4.40−$4.38
30 days ago −$4.40−$4.38
7 days ago −$4.40−$4.38
Now −$3.56−$3.30

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$1.10 −$0.95 +13.6%
Mar 2026 −$1.22 −$1.11 +9.0%
Dec 2025 −$1.14 −$1.34 −17.2%
Sept 2025 −$1.00 −$1.05 −5.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

2 analysts, Oct 2026
Buy2100%
Hold00%
Sell00%

Monthly trend

  1. Oct 2026112
  2. Sep 2026112
  3. Aug 2026112

Counts of recommendations published by analysts covering Atossa Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.9%
of tradable shares
Days to cover
7.43
at average volume
Short interest, 1 month
−10%
to October 15, 2026
Held by institutions
14%
of shares
Held by insiders
1.8%
of shares
Employees
16
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
ATOS+68%−67%+66%+7%−37%−74%
Industry peers (median)−36%−56%−18%−29%−5%−26%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
ATOS50%25%42%42%33%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
ATOS−81%−71%−53%−55%−50%−83%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 9, 2015 to June 24, 2026. Getting back needed a 110986% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.75 – $13.50
From 52-week high
−83.0%
vs 50-day average
−4.8%
vs 200-day average
−41.3%
Volatility (1 year)
91%
Beta vs S&P 500
0.72

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±7.3%
After a week
5 up, 7 down
typical move ±9.9%
After a month
5 up, 7 down
typical move ±16.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 −2.1% +0.6% +7.4% +4.1%
January 9, 2026 0.0% +0.8% −4.6% −50.6%
November 12, 2025 −3.6% −1.6% −8.4% 0.0%
August 12, 2025 +3.9% +1.4% −1.3% +7.9%
May 13, 2025 +22.6% +0.8% +11.9% +2.4%
March 25, 2025 −6.7% −1.0% −13.3% −2.7%
November 12, 2024 −15.4% −0.3% −21.0% −29.0%
August 12, 2024 +11.1% +1.7% +12.8% +29.9%
May 13, 2024 +3.4% +0.5% +7.4% −14.1%
April 1, 2024 +2.2% −0.8% −2.8% −16.1%
November 13, 2023 0.0% +1.8% +15.6% +15.6%
August 14, 2023 −16.2% −0.6% −12.4% −23.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Atossa Therapeutics, Inc.
$0 $200K $400K $600K $800K FY13 Q4 FY14 Q3 FY15 Q2 FY16 Q3 Revenue (TTM), FY13 Q4: $632.6K Revenue (TTM), FY14 Q1: $474K Revenue (TTM), FY14 Q2: $157.8K Revenue (TTM), FY14 Q3: $84.6K Revenue (TTM), FY14 Q4: $40.1K Revenue (TTM), FY15 Q1: $16K Revenue (TTM), FY15 Q2: $6.1K Revenue (TTM), FY15 Q3: $2.7K Revenue (TTM), FY15 Q4: $1.8K Revenue (TTM), FY16 Q1: $1.8K Revenue (TTM), FY16 Q2: $1.8K Revenue (TTM), FY16 Q3: $1.8K $1.8K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY13 Q4 $632.6K
FY14 Q1 $474K
FY14 Q2 $157.8K
FY14 Q3 $84.6K
FY14 Q4 $40.1K
FY15 Q1 $16K
FY15 Q2 $6.1K
FY15 Q3 $2.7K
FY15 Q4 $1.8K
FY16 Q1 $1.8K
FY16 Q2 $1.8K
FY16 Q3 $1.8K
Revenue growth, TTM YoY Atossa Therapeutics, Inc.
-100% -50% 0% 50% FY13 Q4 FY14 Q3 FY15 Q2 FY16 Q3 Revenue growth, TTM YoY, FY13 Q4: 31.3% Revenue growth, TTM YoY, FY14 Q1: -22.3% Revenue growth, TTM YoY, FY14 Q2: -77.9% Revenue growth, TTM YoY, FY14 Q3: -87.6% Revenue growth, TTM YoY, FY14 Q4: -93.7% Revenue growth, TTM YoY, FY15 Q1: -96.6% Revenue growth, TTM YoY, FY15 Q2: -96.1% Revenue growth, TTM YoY, FY15 Q3: -96.8% Revenue growth, TTM YoY, FY15 Q4: -95.6% Revenue growth, TTM YoY, FY16 Q1: -89.0% Revenue growth, TTM YoY, FY16 Q2: -71.4% Revenue growth, TTM YoY, FY16 Q3: -35.2% -35.2%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue growth, TTM YoY
FY13 Q4 31.3%
FY14 Q1 -22.3%
FY14 Q2 -77.9%
FY14 Q3 -87.6%
FY14 Q4 -93.7%
FY15 Q1 -96.6%
FY15 Q2 -96.1%
FY15 Q3 -96.8%
FY15 Q4 -95.6%
FY16 Q1 -89.0%
FY16 Q2 -71.4%
FY16 Q3 -35.2%
Operating margin (TTM) Atossa Therapeutics, Inc.
-800000% -600000% -400000% -200000% 0% FY13 Q4 FY14 Q3 FY15 Q2 FY16 Q3 Operating margin (TTM), FY13 Q4: -1704.9% Operating margin (TTM), FY14 Q1: -2374.2% Operating margin (TTM), FY14 Q2: -7513.7% Operating margin (TTM), FY14 Q3: -13706.2% Operating margin (TTM), FY14 Q4: -30323.0% Operating margin (TTM), FY15 Q1: -81383.6% Operating margin (TTM), FY15 Q2: -212034.4% Operating margin (TTM), FY15 Q3: -501813.2% Operating margin (TTM), FY15 Q4: -725823.4% Operating margin (TTM), FY16 Q1: -672061.6% Operating margin (TTM), FY16 Q2: -589685.9% Operating margin (TTM), FY16 Q3: -459752.8% -459752.8%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY13 Q4 -1704.9%
FY14 Q1 -2374.2%
FY14 Q2 -7513.7%
FY14 Q3 -13706.2%
FY14 Q4 -30323.0%
FY15 Q1 -81383.6%
FY15 Q2 -212034.4%
FY15 Q3 -501813.2%
FY15 Q4 -725823.4%
FY16 Q1 -672061.6%
FY16 Q2 -589685.9%
FY16 Q3 -459752.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 LTM Sept 2016
Income
Revenue 0 0 1 0 0 0
Gross profit −0 0 0 0 −0 —
EBITDA −3 −5 −10 −12 −12 −8
Operating income −3 −5 −11 −12 −13 −8
Net income −3 −5 −11 −15 −16 −9
Diluted EPS −$85.50 −$0.41 −$0.70 −$0.61 −$124.65 —
Growth (year on year)
Revenue — +>999% +31.3% −93.7% −95.6% −35.2%
Margins
Gross margin <−999% 86.4% 21.7% 100.0% <−999% —
EBITDA margin <−999% <−999% <−999% <−999% <−999% <−999%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999%
Net margin <−999% <−999% <−999% <−999% <−999% <−999%
Cash flow
Cash from operations −3 −4 −9 −11 −14 −8
Stock-based pay 0 0 1 1 1 1
Balance sheet
Cash 2 2 6 9 4 4
Total debt 1 0 0 0 0 0
Net debt (negative = net cash) −1 −2 −6 −8 −4 −4
Diluted shares — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ATOS CELZ LYEL AIM IBIO LSTA Median
Revenue, last 12 months $1758 $3000 $27000 $95000 $100000 $100000 $55m
Revenue growth, last 12 months −35.2% −50.0% −55.0% −21.5% −75.0% −90.7% 12.2%
Revenue growth, 3-year average −86.3% −65.6% −91.8% −17.3% −62.4% — 13.1%
Revenue growth, latest quarter −35.2% −100.0% −50.0% 4.0% −100.0% −100.0% 10.2%
Gross margin <−999% 66.9% — −968.5% 59.9% 7.7% 82.8%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average <−999% <−999% <−999% <−999% <−999% <−999% −365.3%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin — <−999% <−999% <−999% <−999% <−999% −162.4%
Free-cash-flow margin, 3-year average — — <−999% <−999% <−999% <−999% −310.0%
Stock pay / revenue >999% 0.0% >999% 0.0% >999% >999% 20.7%
Change in share count −0.7% 61.6% — 49.8% 13.9% 5.1% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$2.6M
Institutions reporting
30
Shares held vs prior quarter
▲ 8.5%
Positions opened / closed
4 / 6

Top buyers and sellers, Q2 2026: 13 institutions bought and 14 sold ; the biggest buyer was Jane Street Group, LLC (+57K shares) and the biggest seller Millennium Management LLC (−20K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Vanguard Capital Management LLC $698,172 362K 26.9% ▲ 3.6%
Ameriprise Financial Inc $498,392 258K 19.2% ▲ 1.2%
Blackrock, Inc. $317,211 164K 12.2% ▲ 23.4%
Renaissance Technologies LLC $254,843 132K 9.8% ▲ 21.1%
Geode Capital Management, LLC $178,343 92K 6.9% ▼ 4.8%
UBS Group AG $159,456 83K 6.1% ▼ 10.2%
Jane Street Group, LLC $109,242 57K 4.2% New
Vanguard Fiduciary Trust Co $101,485 53K 3.9% ▲ 0.7%
Millennium Management LLC $89,760 47K 3.5% ▼ 30.3%
State Street Corp $76,739 40K 3.0% 0.0%
Northern Trust Corp $39,081 20K 1.5% ▲ 5.3%
Susquehanna International Group, LLP $30,058 16K 1.2% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Atossa Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Atossa Therapeutics, Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Roger Marshall(R-KS 1):Purchase, $1,001 - $15,000, traded October 25, 2017, filed August 6, 2018

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • January 9, 2026
  • November 12, 2025
  • August 12, 2025
  • May 13, 2025
  • March 25, 2025

Recent SEC filings

Data status

When each part of this page on Atossa Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Atossa Therapeutics, Inc. in brief

What does Atossa Therapeutics, Inc. do?
Atossa Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Atossa Therapeutics, Inc.'s stock ticker?
Atossa Therapeutics, Inc. trades under the ticker ATOS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Atossa Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Vanguard Capital Management LLC, Ameriprise Financial Inc and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Atossa Therapeutics, Inc.'s market cap?
On December 31, 2015, Atossa Therapeutics, Inc.'s market capitalisation was about $109M and net debt of -$3.7M. Market figures come from third-party market data and may be delayed.
Who are Atossa Therapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Atossa Therapeutics, Inc. are Creative Medical Technology Holdings, Inc., Lyell Immunopharma, Inc., AIM Immunotech Inc., Ibio, Inc. and Lisata Therapeutics, Inc. The side-by-side comparison below sets their revenue, margins and growth against Atossa Therapeutics, Inc.'s.
When is Atossa Therapeutics, Inc.'s next earnings date?
Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Atossa Therapeutics, Inc. announces its own schedule.